Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Unknown 1Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Wilms Tumor 1Sarcoma, Kaposi 1Sarcoma 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Liposarcoma 1Hodgkin Disease 1Her2-negative Metastatic Breast Cancer 1Carcinoma, Ovarian Epithelial 1Acquired Immunodeficiency Syndrome 1AIDS-related Kaposi sarcoma 1

Interventions

tislelizumab 2pembrolizumab 2fludarabine phosphate 2fludarabine 2Nivolumab 2Magnetic Resonance Spectroscopy 2Cyclophosphamide 2sintilimab 1pegfilgrastim 1liposomal doxorubicin 1Vinorelbine 1Vinblastine 1Specimen Handling 1Radiotherapy 1Proton Therapy 1Neuropsychological Tests 1Gemcitabine 1Fluorodeoxyglucose F18 1Doxorubicin 1Dacarbazine 1Brentuximab Vedotin 1Bendamustine Hydrochloride 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Hodgkin Disease × liposomal doxorubicin × Clear all
NCT07021989 2026-06-04

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

University of California, San Francisco

Phase 2 Not yet recruiting
38 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡